M. K. Proteins 14th AGM Set for September 30; Related Party Approvals Pending

CONSUMER-PRODUCTS
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
M. K. Proteins 14th AGM Set for September 30; Related Party Approvals Pending

M. K. Proteins Limited has announced its 14th Annual General Meeting for September 30, 2026. Shareholders will vote on director re-appointments, the appointment of Ms. Aritika Garg as an Independent Director, and significant related party transactions totaling Rs. 135 crore. The cut-off date for e-voting eligibility is September 23, 2026.

M. K. Proteins 14th AGM and Corporate Updates

Revenue grew by 43.02% to Rs. 382.87 crore; Profit After Tax declined by 18.72% to Rs. 6.82 crore.

Reader Takeaway: AGM approval sought for Rs. 135 crore in related party transactions alongside key board leadership changes.

What just happened

M. K. Proteins Limited has officially called for its 14th Annual General Meeting (AGM), scheduled for September 30, 2026. The meeting will be conducted via Video Conferencing. Investors must be on the register by September 23, 2026, to participate in the remote e-voting process, which runs from September 27 to September 29.

Why this matters

The company is seeking shareholder approval for material related party transactions with Kamla Oleo Private Limited (Rs. 80 crore) and Kamla Oils and Fats Private Limited (Rs. 55 crore). Management asserts these are necessary for the supply of essential oils including Rice Bran and Sunflower oil. Crucially, interested related parties will abstain from voting on these specific resolutions.

Governance and Board Update

There is a transition in board composition. Ms. Laxmi Mandal has resigned as an Independent Director, with Ms. Aritika Garg stepping in as an Additional Independent Director effective August 22, 2026. Shareholders will also vote on the formal re-appointment of Mr. Raj Kumar, who retires by rotation.

Context metrics

While the company recorded strong top-line growth of 43% year-on-year, the bottom-line profitability saw a compression of nearly 19%. The company continues to operate with a CARE CRISIL A credit rating for both long and short-term debt facilities, reflecting stable creditworthiness despite the profit dip.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.